Search - tctmd.com

Displaying 41 - 60 of 168

Sort: Relevancy | Date

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

Presentation TCT 2021

DurAVR THV: A Novel 3D Single Piece Valve Designed for Improved Durability and Hemodynamics

Presenter: Samir Kapadia

November 05, 2021

News Daily News

TAVR Yields Similar Success in Failed TAVR or Surgical Valves

Caitlin E. Cox

January 07, 2021

News Daily News

Making Sense of MI: EXCEL and SYNTAX Tackle Event Definitions

Michael O'Riordan

September 28, 2020

News Daily News

SAVR After Failed TAVR: Rare and Risky, Registry Study Finds

Yael L. Maxwell

June 10, 2020

News Conference News CRT 2020

Positive Early Data for TAVR in Low-Risk Patients With Bicuspid Valves

Michael O'Riordan

February 27, 2020

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Industry News

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

August 16, 2019

News Daily News

New TAVR NCD a ‘Missed Opportunity’ to Align SAVR, TAVR Quality

Shelley Wood

June 27, 2019

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

News Conference News TVT 2019

Transcarotid Bests Aortic/Apical for Alternative TAVR Access: TVT Registry

Shelley Wood

June 17, 2019

Presentation TVT 2019

Illustrative Cases

Presenter: Michael Reardon

June 13, 2019

News Daily News

Similar Mortality, Higher Early Stroke Risks in TAVR for Bicuspid Aortic Stenosis

Michael O'Riordan

June 11, 2019

News Daily News

FDA Approves Lotus Edge, Ushering Third Device Into US Market

Shelley Wood

April 24, 2019

Presentation SIF 2019

Next Generation TAVR Devices

Presenter: Michael J Reardon

March 30, 2019

Presentation SIF 2019

Top 4 Structural Trials of the Last Year

Presenter: Michael J Reardon

March 27, 2019

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

Presentation ACC 2019

Primary Results From the Evolut Low Risk Trial

Presenter: Michael J. Reardon

March 17, 2019

News Daily News

Lotus Maintains Good Safety, Efficacy at 2 Years, Though Questions Persist Over Permanent Pacing

Yael L. Maxwell

March 01, 2019

Advertisement

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

DurAVR THV: A Novel 3D Single Piece Valve Designed for Improved Durability and Hemodynamics

TAVR Yields Similar Success in Failed TAVR or Surgical Valves

Making Sense of MI: EXCEL and SYNTAX Tackle Event Definitions

SAVR After Failed TAVR: Rare and Risky, Registry Study Finds

Positive Early Data for TAVR in Low-Risk Patients With Bicuspid Valves

FDA Expands TAVR Indication to Low-Risk Patients

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

New TAVR NCD a ‘Missed Opportunity’ to Align SAVR, TAVR Quality

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Transcarotid Bests Aortic/Apical for Alternative TAVR Access: TVT Registry

Illustrative Cases

Similar Mortality, Higher Early Stroke Risks in TAVR for Bicuspid Aortic Stenosis

FDA Approves Lotus Edge, Ushering Third Device Into US Market

Next Generation TAVR Devices

Top 4 Structural Trials of the Last Year

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Primary Results From the Evolut Low Risk Trial

Lotus Maintains Good Safety, Efficacy at 2 Years, Though Questions Persist Over Permanent Pacing

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content